Mesoblast Ltd has released a press release.
MSB Licensee Files For Skin Disease Marketing Approval
Filed with ASX ·
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Earlier from Mesoblast
- MSB Draws US$15 Million From Existing Facility
- P3 Trial of MSBs Cell Therapy in CHF Completes Recruitment
- Response to ASX query
- LVAD Results Webcast Presentation
- LVAD Trial Results Provide Potential Regulatory Pathway
Later from Mesoblast
- MoU for Confirmatory Trial for GI Bleeding in LVAD Patients
- Mesoblast Initiates Rolling Submission of BLA for GvHD
- MSB Provides Q3 Financial Results and Operational Highlights
- MSB Expands JCR Partnership To Brain Disease In Newborns
- FDA Grants Revascor Orphan Drug For End Stage CHF With LVADs
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast